Since Aptose Biosciences Inc. (NASDAQ:APTO) and Galapagos NV (NASDAQ:GLPG) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences Inc.	N/A	0.00	25.89M	-0.81	0.00
Galapagos NV	N/A	0.00	N/A	-1.69	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Aptose Biosciences Inc. and Galapagos NV.

Profitability

Table 2 has Aptose Biosciences Inc. and Galapagos NV’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences Inc.	0.00%	0%	0%
Galapagos NV	0.00%	0%	0%

Analyst Ratings

In next table is given Aptose Biosciences Inc. and Galapagos NV’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Aptose Biosciences Inc.	0	0	2	3.00
Galapagos NV	0	0	6	3.00

Aptose Biosciences Inc.’s upside potential currently stands at 187.96% and an $5.5 average price target. Galapagos NV on the other hand boasts of a $126.5 average price target and a 25.45% potential upside. The information presented earlier suggests that Aptose Biosciences Inc. looks more robust than Galapagos NV as far as analyst opinion.

Insider and Institutional Ownership

Institutional investors held 35.1% of Aptose Biosciences Inc. shares and 19.34% of Galapagos NV shares. About 20.4% of Aptose Biosciences Inc.’s share are held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aptose Biosciences Inc.	-8.61%	-12.18%	-30.56%	-51.73%	12.06%	-6.7%
Galapagos NV	1.58%	-6.19%	5.07%	0.46%	20.27%	9.12%

For the past year Aptose Biosciences Inc. has -6.7% weaker performance while Galapagos NV has 9.12% stronger performance.

Summary

On 3 of the 5 factors Aptose Biosciences Inc. beats Galapagos NV.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.